TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Fruquintinib
Related studies linked through entity extraction aliases.
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
- Status
- RECRUITING
- Phase
- PHASE2
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
- Status
- SUSPENDED
- Phase
- PHASE2
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT
- Status
- UNKNOWN
- Phase
- PHASE2
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
Fruquintinib DDI Study With P-gp and BCRP Substrates
- Status
- COMPLETED
- Phase
- PHASE1
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
- Status
- UNKNOWN
- Phase
- PHASE2